A lackluster performance in clinical trials of the monoclonal antibody aducanumab has left some experts unconvinced of its benefit.

Now more than ever before, recruiting patients for a research study doesn’t have to mean getting them to leave their homes.

Johnson & Johnson’s one-shot immunization could reach people’s arms as early as March 2.

As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

Vaccine experts divided on whether that level of protection is too low or too demanding.

Hydroxychloroquine and chloroquine, once thought to be promising COVID-19 treatments, come with serious heart risks.

Kennedy, who succumbed to COVID-19, served as commissioner of the FDA and editor-in-chief of Science, and is credited with helping to transform Stanford into a top research university.

Abbott’s ID NOW test missed the most positive samples among five products given the green light by the FDA to use during the pandemic.

Assembling the first COVID-19 test kits in the same room as coronavirus material, along with other practices that didn’t follow protocol, made the tests unusable, officials say.

The search for SARS-CoV-2 RNA in 60 saliva samples yielded the same results as conventional nasal swab tests taken from the same patients.

The antiviral disables RNA replication machinery in MERS and SARS viruses. Can it beat back SARS-CoV-2?

The sponsors of upwards of 1,000 clinical trials may be forced to publish data that have gone unpublished over a 10-year period.

Current bills in Congress would apply similar provisions to all federal agencies.

The US Food and Drug Administration authorizes the distribution of the 2019-nCoV diagnostic to state health departments and other facilities.

The drug Vyondys 53 has met a surrogate endpoint of protein production, but there’s no clear proof it has a clinical benefit.